Harpoon Drops After Prostate Cancer Candidate Shows Cytokine-Related Adverse Events
- Harpoon Therapeutics Inc HARP 24.09% has announced interim data from the ongoing dose-escalation portion of a Phase 1/2a trial evaluating HPN424 in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Data were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
- HPN424 targets prostate-specific membrane antigen (PSMA) and is based on Harpoon's proprietary Tri-specific T cell Activating Construct (TriTAC) platform designed to recruit a patient's immune cells to kill tumor cells.
- As of April 23, the data cutoff date, 89 patients have been dosed across 13 cohorts at fixed doses of 1.3 to 160 ng/kg and in step dosing cohorts up to 300ng/kg administered as a weekly intravenous infusion.
- Antitumor activity included one confirmed partial response, PSA declines, and circulating tumor cell (CTC) reductions.
- Treatment duration of over 24 weeks was observed in 15 of 74 (20%) of patients, including 8 of 17 (47%) chemo-naïve patients.
- CRS and transaminitis events were observed most often in Cycle 1, with diminished frequency and severity in subsequent cycles.
- Dose Limiting Toxicities (DLTs) were observed at doses ranging from 96 to 300ng/kg and did not limit escalation, and Maximum Tolerated Dose was not reached.
- 2/89 patients discontinued treatment due to treatment-related AEs.
- Harpoon's management will host a webcast and conference call today at 4 p.m. ET.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.